Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

12P - The efficacy of EGFR tyrosine kinase inhibitors and its clinical prognostic factors in lung adenocarcinoma patients harboring different types of EGFR mutations: Real World Data

Date

15 Oct 2022

Session

Poster display session

Presenters

Marina Vitorino

Citation

Annals of Oncology (2022) 33 (suppl_8): S1383-S1430. 10.1016/annonc/annonc1095

Authors

M. Vitorino, R. Ferreira, A.F. Chaves

Author affiliations

  • Hospital Professor Doutor Fernando Fonseca, Amadora/PT
More

Abstract 12P

Background

Lung cancer has the highest incidence and mortality among all cancers, with a 5-year survival rate of 15%. Presently, epidermal growth factor receptor (EGFR) mutation is the most common type of gene mutations detected in patients (pts) with advanced non-small-cell lung cancer, and EGFR is identified as the therapeutic target of EGFR tyrosine kinase inhibitors (TKIs). EGFR-TKIs have become the standard treatment. However, the most of the trials were developed in Asian countries, with a lack of data in western population.

Methods

This retrospective study aimed to review the medical records of EGFR- mutant advanced lung adenocarcinoma (LA) undergoing EGFR-TKIs treatment from 2015 to 2021, so as to examine the association of clinical factors with EGFR-TKI efficacy.

Results

Of the 53 stage IV LA pts enrolled in this study, 9 were treated with more than one TKI. The mean age was 74,2 years old, 32 pts were non-smoker females and 38 had ECOG-PS 0-1. The mutations del19 or 21 L861G were the most frequent (23 and 20 pts respectively). The 20 T790M mutation was detected in 6 pts. First-line TKI (Gefitinib, Afatinib, Erlotinib and Osimertinib) were used in 26 pts and prior chemotherapy was preferred in 29 pts. A 24% objective response rate (ORR) and 67% disease control rate were observed for EGFR-TKIs treatment in all lines. Higher ORR was seen in patients with 0/1 ECOG scores than those with 2 or greater scores (p=0.046). The subjects had a progression free survival (PFS) of 17,8 months (p<0,01; 95% CI:12.9-22.84) and an overall survival (OS) of 27,5 months (p<0.01; 95% CI: 18.27-36.823). The median PFS was longer in pts treat with first-line TKI (p=0.029). The multivariate analysis indicated that ECOG-PS (p=0.04) and bone metastasis (p=0.036) were independent prognostic factors for OS.

Conclusions

The EGFR-TKI therapy results in survival benefits for EGFR-mutant advanced LA patients. ECOG-PS and bone metastasis were independent prognostic factors for OS.

Legal entity responsible for the study

Hospital Professor Doutor Fernando Fonseca.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.